Payment overview · 2025
General Payments
$152.16
7 reported records · 5 companies
Healthcare provider profile · identity verified
Lance K Dyess, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ELBA, AL · NPI 1912980269
Verified facts
What the public records show
CMS Open Payments records show Lance K Dyess, M.D. received $152.16 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.18 | 32.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $41.75 | 27.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.93 | 17.0% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $21.42 | 14.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.88 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $119.89 | 6 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $41.75 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
129 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 722 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 693 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 500 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 94 |
| Lisinopril | Lisinopril | 444 | 88 |
| Losartan Potassium | Losartan Potassium | 386 | 91 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 378 | 64 |
| Trazodone Hcl | Trazodone Hcl | 317 | 45 |
| Potassium Chloride | Potassium Chloride | 309 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 300 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 299 | 44 |
| Tramadol Hcl | Tramadol Hcl | 290 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 279 | 73 |
| Furosemide | Furosemide | 266 | 46 |
| Sertraline Hcl | Sertraline Hcl | 264 | 39 |
| Simvastatin | Simvastatin | 251 | 49 |
| Eliquis | Apixaban | 246 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 227 | 21 |
| Gabapentin | Gabapentin | 218 | 51 |
| Allopurinol | Allopurinol | 207 | 46 |
| Jardiance | Empagliflozin | 200 | 36 |
| Olanzapine | Olanzapine | 191 | suppressed |
| Memantine Hcl | Memantine Hcl | 183 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 165 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 33 |
| Mounjaro | Tirzepatide | 161 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 157 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 21 |
| Meclizine Hcl | Meclizine Hcl | 150 | 19 |
| Metformin Hcl | Metformin Hcl | 150 | 48 |
| Ondansetron Hcl | Ondansetron Hcl | 148 | 39 |
| Buspirone Hcl | Buspirone Hcl | 147 | 29 |
| Carvedilol | Carvedilol | 147 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 141 | 20 |
| Donepezil Hcl | Donepezil Hcl | 137 | 16 |
| Lorazepam | Lorazepam | 137 | 18 |
| Farxiga | Dapagliflozin Propanediol | 129 | 23 |
| Glimepiride | Glimepiride | 128 | 26 |
| Levetiracetam | Levetiracetam | 128 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 38 |
| Januvia | Sitagliptin Phosphate | 124 | 23 |
| Prednisone | Prednisone | 122 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 17 |
| Nifedipine Er | Nifedipine | 113 | 32 |
| Alprazolam | Alprazolam | 108 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 104 | 15 |
| Risperidone | Risperidone | 104 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 102 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 100 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 99 | suppressed |
| Pregabalin | Pregabalin | 99 | 19 |
| Doxepin Hcl | Doxepin Hcl | 95 | 11 |
| Omeprazole | Omeprazole | 95 | 33 |
| Alendronate Sodium | Alendronate Sodium | 89 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 88 | 14 |
| Meloxicam | Meloxicam | 83 | 12 |
| Montelukast Sodium | Montelukast Sodium | 83 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 81 | suppressed |
| Ozempic | Semaglutide | 81 | 17 |
| Trulicity | Dulaglutide | 79 | 13 |
| Sucralfate | Sucralfate | 77 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | suppressed |
| Bumetanide | Bumetanide | 75 | suppressed |
| Cefdinir | Cefdinir | 75 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 11 |
| Rexulti | Brexpiprazole | 69 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 19 |
| Carbamazepine | Carbamazepine | 66 | suppressed |
| Temazepam | Temazepam | 66 | suppressed |
| Xarelto | Rivaroxaban | 66 | suppressed |
| Cephalexin | Cephalexin | 64 | 39 |
| Ziprasidone Hcl | Ziprasidone Hcl | 62 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 16 |
| Topiramate | Topiramate | 59 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 18 |
| Colchicine | Colchicine | 55 | 18 |
| Spironolactone | Spironolactone | 54 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 15 |
| Leflunomide | Leflunomide | 52 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 52 | suppressed |
| Baclofen | Baclofen | 51 | suppressed |
| Vascepa | Icosapent Ethyl | 51 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | suppressed |
| Azithromycin | Azithromycin | 49 | 39 |
| Clonidine Hcl | Clonidine Hcl | 48 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 47 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 36 |
| Cilostazol | Cilostazol | 43 | suppressed |
| Perphenazine | Perphenazine | 43 | suppressed |
| Mupirocin | Mupirocin | 41 | 33 |
| Diazepam | Diazepam | 40 | suppressed |
| Calcium Acetate | Calcium Acetate | 38 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Hydrocortisone | Hydrocortisone | 34 | 26 |
| Metformin Hcl Er | Metformin Hcl | 34 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 27 | 22 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 20 |
| Atenolol | Atenolol | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Famotidine | Famotidine | 23 | 12 |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 13 |
| Finasteride | Finasteride | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Alyacen | Norethindrone-Ethin. Estradiol | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $152.16 · 7 records | Novo Nordisk Inc | Auvelity, BREZTRI, Kerendia, Ozempic, Rybelsus | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error